medical devices

Semaglutide vs. Tirzepatide: Novo Nordisk Gains in India A scientific image depicting Semaglutide, Novo Nordisk, Eli Lilly, and an upward arrow indicating market competition in India.

A scientific image depicting Semaglutide, Novo Nordisk, Eli Lilly, and an upward arrow indicating market competition in India.

Semaglutide vs. Tirzepatide: Novo Nordisk Gains in India

sivam March 8, 2026

Novo Nordisk's semaglutide is rapidly gaining ground in India's anti-obesity market, challenging Eli Lilly's tirzepatide. Discover how...

India to Lead Global Homoeopathy Market with Quality Certifications India map with glowing nodes, global map, pharmaceutical equipment, and quality certification logos (GMP, ISO 9001, AYUSH Premium).

India map with glowing nodes, global map, pharmaceutical equipment, and quality certification logos (GMP, ISO 9001, AYUSH Premium).

India to Lead Global Homoeopathy Market with Quality Certifications

sivam March 8, 2026

India is set to dominate the global homoeopathy market, driven by clinical expertise, strong practitioner networks, and...

Middle East Conflict Impacts Medical Tourism: India’s Shift Doctors in front of a hospital with a world map showing conflict zones and new market opportunities for medical devices.

Doctors in front of a hospital with a world map showing conflict zones and new market opportunities for medical devices.

Middle East Conflict Impacts Medical Tourism: India’s Shift

sivam March 8, 2026

The Middle East conflict disrupts medical tourism, pushing Indian hospitals to diversify. Explore how they're adapting to...

Cipla Recalls Cancer Drug in US Due to Manufacturing Flaw Two scientists in a sterile lab, with a "RECALL" box in the foreground and a robot arm spilling pills.

Two scientists in a sterile lab, with a "RECALL" box in the foreground and a robot arm spilling pills.

Cipla Recalls Cancer Drug in US Due to Manufacturing Flaw

sivam March 8, 2026

Cipla USA recalls Nilotinib Capsules, a cancer drug, due to a manufacturing issue. The Class III recall...

FDA Vaccine Chief Resigns Amidst Controversy Image related to the FDA Vaccine Chief resignation, with visuals of a Capitol building, a syringe, and resignation papers.

Image related to the FDA Vaccine Chief resignation, with visuals of a Capitol building, a syringe, and resignation papers.

FDA Vaccine Chief Resigns Amidst Controversy

sivam March 7, 2026

Vinay Prasad, FDA's vaccine chief, resigns amidst controversy over Covid-19 vaccine policies. Explore the details of his...

Obesity & Diabetes Crisis: A Global Health Tsunami An impactful visual representing the global health crisis of obesity and diabetes with relevant medical and policy icons.

An impactful visual representing the global health crisis of obesity and diabetes with relevant medical and policy icons.

Obesity & Diabetes Crisis: A Global Health Tsunami

sivam March 6, 2026

Peter Piot warns of a global 'health tsunami' due to rising obesity and diabetes, especially impacting India....

Glenmark’s Fluticasone Inhaler Approved by US FDA A modern fluticasone inhaler with Glenmark branding, glowing medical graphics, and a "US FDA APPROVED" label, against a blurred pharmaceutical manufacturing background.

A modern fluticasone inhaler with Glenmark branding, glowing medical graphics, and a "US FDA APPROVED" label, against a blurred pharmaceutical manufacturing background.

Glenmark’s Fluticasone Inhaler Approved by US FDA

sivam March 4, 2026

Glenmark Pharmaceuticals secures US FDA approval for its fluticasone propionate inhaler. This strategic move strengthens their respiratory...

Urban India’s Metabolic Health Crisis: Obesity & Diabetes Surge An image combining a bustling Indian city with medical representations of obesity, diabetes, and related medical devices.

An image combining a bustling Indian city with medical representations of obesity, diabetes, and related medical devices.

Urban India’s Metabolic Health Crisis: Obesity & Diabetes Surge

sivam March 4, 2026

Explore the metabolic health crisis in urban India, with rising obesity and diabetes rates. Learn about GLP-1...

ZYOG1: The Oral GLP-1 That India Couldn’t Launch Conceptual image showing a modern GLP-1 device and a DNA helix transitioning to a dilapidated factory with 'INDIA' written on it.

Conceptual image showing a modern GLP-1 device and a DNA helix transitioning to a dilapidated factory with 'INDIA' written on it.

ZYOG1: The Oral GLP-1 That India Couldn’t Launch

sivam March 3, 2026

Discover the story of ZYOG1, Zydus's pioneering oral GLP-1 agonist for diabetes and weight loss. Learn about...

AIIMS Milestone: Child Hears After Brain Stem Implant A surgeon's hands delicately hold a brain stem implant near a child's ear, with medical monitors in the background.